Dorothy Brach

Background

About Dorothy Brach

Experienced cancer biologist with >17 years in drug discovery in companies ranging from large pharma to small biotech. Effective at working on multiple projects simultaneously with a strong sense of urgency supporting cross-functional teams, fast learner, valued by senior management as a key contributor and true team player with unmatched passion and enthusiasm.~Core skills: • Proficient in mammalian tissue culture, western blot, assay development, apoptosis and cell cycle analysis, DNA damage response, combination studies, viral mimicry and inflammatory pathways, epigenetics, genetic knockdown by siRNA/LNA gapmers, overexpression using plasmids. •Target Engagement assays: NanoBRET, NanoBiT, In Cell Western, ELISA, qPCR, TRIFC and KISS proximity assays •CRO management: in vitro, ex vivo, in vivo studies •Data analysis software: CDD Vault, Dotmatics, Live Design, Arxspan •Instrumentation: Incucyte, Quantstudio, PheraSTAR, Spectramax, LICOR, Guava EasyCyte, Cytation ~Publications: • Lampe JW, Alford JS, Boriak-Sjodin PA, Brach D, Cosmopoulos K, Duncan KW, Eckley ST, Foley MA, Harvey DM, Motwani V, Munchhof MJ, Raimondi A, Riera TV, Tang C, Thomenius MJ, Totman J, Farrow NA.(2021) Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies. ACS Med Chem Lett. Aug 24;12(10):1539-1545. • Thomenius MJ, Totman J, Harvey D, Mitchell LH, Riera TV, Cosmopoulos K, Brach D, et al.(2018) Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. PLoSONE 13(6):e0197372. • Brach, D, Johnston-Blackwell, D, Drew, A, Lingaraj, T, Motwani, V, Warholic, NA, Feldman, I, Plescia, C, Smith, JJ, Copeland, RA, Keilhack, H, Chan-Penebre, E, Knutson, SK, Ribich, SA, Raimondi, A, Thomenius, MJ.(2017) EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL. Molecular Cancer Therapeutics, 16(11); 2586–97. •Klaus CR, Iwanowicz D, Johnston D, Campbell CA, Smith JJ, Moyer MP, Copeland RA, Olhava EJ, Scott MP, Pollock RM, Daigle SR, Raimondi A.(2014). DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells. J Pharmacol Exp Ther, 350(3):646-56 •Balibar, C, Shen, X, McGuire (Iwanowicz), D, Yu, D, McKenney, D, Tao, J.(2010). cwrA, a gene that specifically responds to cell wall damage in Staphylococcus aureus. Microbiology, 156, 1372-1383.~